Photo from wikipedia
Critical Care Medicine www.ccmjournal.org 1815 4. Pandharipande P, Shintani A, Peterson J, et al: Lorazepam is an independent risk factor for transitioning to delirium in intensive care unit patients. Anesthesiology… Click to show full abstract
Critical Care Medicine www.ccmjournal.org 1815 4. Pandharipande P, Shintani A, Peterson J, et al: Lorazepam is an independent risk factor for transitioning to delirium in intensive care unit patients. Anesthesiology 2006; 104:21–26 5. Kolla BP, Lovely JK, Mansukhani MP, et al: Zolpidem is independently associated with increased risk of inpatient falls. J Hosp Med 2013; 8:1–6 6. Miyamoto M: Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: A novel therapeutic drug for sleep disorders. CNS Neurosci Ther 2009; 15:32–51 7. Red Book: Micromedex Solutions. Ann Arbor, MI, Truven Health Analytics. Available at: http://www.micromedexsolutions.com. Accessed August 22, 2019 8. Erland LA, Saxena PK: Melatonin natural health products and supplements: Presence of serotonin and significant variability of melatonin content. J Clin Sleep Med 2017; 13:275–281 9. Hatta K, Kishi Y, Wada K, et al; DELIRIA-J Group: Preventive effects of ramelteon on delirium: A randomized placebo-controlled trial. JAMA Psychiatry 2014; 71:397–403 10. Takeda Pharmaceutical Company, Ltd. Rozerem (ramelteon) [package insert]. U.S. Food and Drug Administration website. Revised December 2018. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021782s021lbl.pdf. Accessed August 21, 2019 11. Bourne RS, Mills GH, Minelli C: Melatonin therapy to improve nocturnal sleep in critically ill patients: Encouraging results from a small randomised controlled trial. Crit Care 2008; 12:R52 12. Baumgartner L, Lam K, Lai J, et al: Effectiveness of melatonin for the prevention of intensive care unit delirium. Pharmacotherapy 2019; 39:280–287 13. Ng KT, Teoh WY, Khor AJ: The effect of melatonin on delirium in hospitalised patients: A systematic review and meta-analyses with trial sequential analysis. J Clin Anesth 2019; 59:74–81 14. Nishikimi M, Numaguchi A, Takahashi K, et al: Effect of administration of ramelteon, a melatonin receptor agonist, on the duration of stay in the ICU: A single-center randomized placebo-controlled trial. Crit Care Med 2018; 46:1099–1105 15. Thom R, Bui M, Rosner B, et al: Ramelteon is not associated with improved outcomes among critically ill delirious patients: A single-center retrospective cohort study. Psychosomatics 2019; 60:289–297 16. Jaiswal SJ, Vyas AD, Heisel AJ, et al: Ramelteon for Prevention of Postoperative Delirium: A Randomized Controlled Trial in Patients Undergoing Elective Pulmonary Thromboendarterectomy. Crit Care Med 2019; 47:1751–1758 17. Booka E, Tsubosa Y, Matsumoto T, et al: Postoperative delirium after pharyngolaryngectomy with esophagectomy: A role for ramelteon and suvorexant. Esophagus 2017; 14:229–234